Literature DB >> 2455308

Potassium-sparing diuretics.

J D Horisberger1, G Giebisch.   

Abstract

Amiloride, triamterene, and the spirolactones are potassium-sparing diuretics which act on the distal parts of the nephron, from the late distal tubule to the collecting duct. In these segments, active sodium reabsorption occurs through the following mechanism: sodium ions enter the cell through specific channels present in the luminal membrane and are extruded out of the cell into the peritubular medium by a sodium-potassium exchange pump, the Na-K-ATPase. Amiloride in micromolar concentrations reduces the sodium transport by blocking the luminal membrane sodium channel. Triamterene has a similar effect, although with a lower affinity; the available studies do not allow to determine if an inhibitory effect of triamterene on the Na-K-ATPase plays an additional role in its diuretic action. The spirolactones are competitive inhibitors of aldosterone, the mineralocorticoid hormone which promotes sodium reabsorption by increasing both the number of active sodium channels in the luminal membrane and the number of active Na-K pumps in the peritubular membrane. By the inhibitory effect on the electrogenic sodium transport, amiloride, triamterene, and the spirolactones decrease the lumen-negative transepithelial potential difference. This reduces the driving force for potassium movement into the tubular lumen and thus decreases potassium excretion.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2455308     DOI: 10.1159/000173130

Source DB:  PubMed          Journal:  Ren Physiol        ISSN: 0378-5858


  14 in total

Review 1.  The amiloride receptor.

Authors:  J D Horisberger; A Puoti; C Canessa; B C Rossier
Journal:  Clin Investig       Date:  1994-09

2.  Renal tubular lithium reabsorption in potassium-depleted rats.

Authors:  D G Shirley; S J Walter
Journal:  J Physiol       Date:  1997-06-15       Impact factor: 5.182

Review 3.  Renal and extrarenal sites of action of diuretics.

Authors:  G Giebisch; G Klein-Robbenhaar; J Klein-Robbenhaar; K Ratheiser; R Unwin
Journal:  Cardiovasc Drugs Ther       Date:  1993-01       Impact factor: 3.727

Review 4.  [Diuretics as a problem-Pharmacokinetics, pharmacodynamics, use in edema or hypertension].

Authors:  Mark Dominik Alscher
Journal:  Internist (Berl)       Date:  2021-01-25       Impact factor: 0.743

Review 5.  Pharmacotherapy of ascites associated with cirrhosis.

Authors:  P Ginès; V Arrovo; J Rodés
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

6.  Amiloride enhances the anticonvulsant action of various antiepileptic drugs in the mouse maximal electroshock seizure model.

Authors:  Jarogniew J Luszczki; Katarzyna M Sawicka; Justyna Kozinska; Monika Dudra-Jastrzebska; Stanislaw J Czuczwar
Journal:  J Neural Transm (Vienna)       Date:  2008-11-22       Impact factor: 3.575

7.  A micropuncture study of renal tubular lithium reabsorption in sodium-depleted rats.

Authors:  S J Walter; B Sampson; D G Shirley
Journal:  J Physiol       Date:  1995-03-01       Impact factor: 5.182

8.  Initial experience with conivaptan use in critically ill infants with cardiac disease.

Authors:  Ryan C Jones; Surender Rajasekaran; Mark Rayburn; Joseph D Tobias; Robert M Kelsey; Glenn T Wetzel; Antonio G Cabrera
Journal:  J Pediatr Pharmacol Ther       Date:  2012-01

Review 9.  Renal haemodynamic and protective effects of renoactive drugs in type 2 diabetes: Interaction with SGLT2 inhibitors.

Authors:  Rosalie A Scholtes; Michaël J B van Baar; Megan D Kok; Petter Bjornstad; David Z I Cherney; Jaap A Joles; Daniël H van Raalte
Journal:  Nephrology (Carlton)       Date:  2021-01-04       Impact factor: 2.506

Review 10.  Aldosterone and aldosterone receptor antagonists in patients with chronic heart failure.

Authors:  Jean M Nappi; Adam Sieg
Journal:  Vasc Health Risk Manag       Date:  2011-06-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.